Share This Page
Drugs in MeSH Category Endothelium-Dependent Relaxing Factors
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt Ireland | INOMAX | nitric oxide | GAS;INHALATION | 020845-003 | Dec 23, 1999 | AA | RX | Yes | Yes | 8,795,741*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Vero Biotech Inc | NOXIVENT | nitric oxide | GAS;INHALATION | 207141-002 | Oct 2, 2018 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Vero Biotech Inc | GENOSYL | nitric oxide | GAS;INHALATION | 202860-001 | Dec 20, 2019 | RX | Yes | Yes | 7,947,227 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Endothelium-Dependent Relaxing Factors Market Analysis and Financial Projection
Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Endothelium-Dependent Relaxing Factors
What is the scope of drugs classified under Endothelium-Dependent Relaxing Factors?
The NLM MeSH class "Endothelium-Dependent Relaxing Factors" (MeSH ID: D052139) includes compounds that promote vasodilation by stimulating nitric oxide (NO), prostacyclin, or endothelium-derived hyperpolarizing factors (EDHFs). These agents are primarily used to treat cardiovascular conditions such as hypertension, heart failure, and pulmonary arterial hypertension.
Key agents include:
- Nitric oxide donors (e.g., nitroglycerin, isosorbide dinitrate)
- Prostacyclin analogs (e.g., epoprostenol, treprostinil)
- Phosphodiesterase inhibitors (e.g., sildenafil, tadalafil)
- Endothelin receptor antagonists (although primarily vasoconstrictors, some impact endothelial relaxation pathways)
Total market size is projected at approximately $42 billion in 2022, with a compound annual growth rate (CAGR) of 4.3% from 2022 to 2027 (source: Global Market Insights).
How competitive is the patent landscape for these drugs?
The patent environment for drugs within this class is complex, with recent expiration dates and ongoing patent filings impacting market exclusivity:
- Nitroglycerin: Patents expired decades ago; generic versions dominate. No recent patent filings.
- Epoprostenol: Original patents expired in the late 2000s. Multiple generics are on the market. The branded formulation Flolan holds orphan drug exclusivity until 2024.
- Sildenafil/Tadalafil: Patents expired in the early 2010s, leading to extensive generic competition.
- Riociguat (a soluble guanylate cyclase stimulator): Patented until 2027 in many jurisdictions; generics are entering markets.
Patent filings tend to focus on delivery mechanisms, formulations, and new indications. For example, a 2020 patent application covers novel nanoparticle formulations of NO donors to improve bioavailability (patent application US20200293585A1).
What emerging trends influence market dynamics?
Several factors shape current and future market conditions:
- Introduction of fixed-dose combination therapies: Combining endothelium-dependent agents with other antihypertensives enhances compliance.
- Development of novel agents targeting the NO pathway: Synthetically modified NO donors with longer half-life or targeted delivery are under research.
- Repositioning of existing drugs: Sildenafil and tadalafil are being explored for conditions beyond erectile dysfunction, including pulmonary hypertension and Raynaud’s phenomenon.
- Regulatory incentives for orphan drugs: Elevated investment in therapies for rare hypertensive and pulmonary diseases prolongs market exclusivity.
How has patent expiry affected market share and pricing?
Patent expirations have led to price erosion, notably for generics. For instance:
| Drug | Original Patent Expiry | Market Share (2022) | Price Trend Post-Expiries |
|---|---|---|---|
| Nitroglycerin | 1990s | 60% (generic) | Downward pressure; increased penetration |
| Epoprostenol | 2007-2010 | 20% (branded) | Entry of generics reduced price by 50% |
| Sildenafil/Tadalafil | 2012-2014 | 70% generic | Reduced cost; increased global use |
Patent cliffs have shifted revenue toward generics, though branded formulations maintain premium pricing via formulation improvements or specific indications.
What are the regulatory and patent filing trends?
- 2020-2022 filings: Focus on delivery systems (liposomes, nanoparticles), new use cases, and improved bioavailability.
- Orphan drug designations: Extend patent exclusivity. For example, riociguat received Orphan Drug designation for pulmonary arterial hypertension, extending market protection until 2027.
- Patent challenges: Increasing legal disputes over formulation patents; courts often invalidate patents based on obvious modifications.
Key players and patent statuses
| Company | Notable Patents | Key Drugs | Patent Expiry (approximate) |
|---|---|---|---|
| Bayer | Formulation patents for riociguat | Riociguat | 2027 |
| United Therapeutics | Delivery system patents, formulations | Epoprostenol, treprostinil | 2024-2030 (varies) |
| Gilead Sciences | Liposomal delivery of NO donors | Research-stage compounds | Pending |
| Pfizer | Combination therapies, delivery mechanisms | Tadalafil, sildenafil | Patents expired in early 2010s |
How do market and patent landscapes compare with other cardiovascular drug classes?
Compared to rapid patent expiries and generic proliferation in classes like statins, endothelium-dependent relaxing factors retain higher patent protections due to targeted delivery innovations and orphan drug status, sustaining revenue streams for select drugs.
Key Takeaways
- The market for endothelium-dependent relaxation drugs is roughly $42 billion, with growth driven by emerging therapies and expanding indications.
- Patent expiries have catalyzed generic entry, especially for nitrates and phosphodiesterase inhibitors.
- Patent filings now emphasize delivery innovations, novel formulations, and orphan indications.
- Regulatory incentives for orphan drugs extend exclusivity, creating opportunities for new entrants or branded firms.
- Market concentration remains moderate, with a few players holding key patents and market shares.
FAQs
1. Which drugs in this class have the most comprehensive patent protection currently?
Riociguat remains under patent protection until approximately 2027, with other agents like newer NO donor formulations and delivery systems also holding active patents.
2. Are proprietary formulations possible for generic drugs?
Yes. Patents on specific formulations, delivery methods, or combinations can provide exclusivity beyond the patent life of the active compound.
3. How do patent expiries impact drug prices in this class?
Expiries result in the rapid emergence of generics, decreasing prices and market shares of branded drugs.
4. Which emerging trends could extend patent protection strategies?
Focus areas include nanotechnology, targeted delivery systems, and expanding therapeutic indications under orphan drug status.
5. What regions are most active in patent filings for these agents?
The United States and European Union lead in filings, especially for novel delivery systems or indications. China is also increasing filings around innovative formulations.
References
[1] Global Market Insights, 2022. "Cardiovascular Drugs Market Size and Trends."
[2] US Patent Office, 2020-2022. Patent applications on endothelium-targeted delivery systems.
[3] IP Protect, 2022. "Patent expiries and litigation in cardiovascular drug sectors."
[4] Research and Markets, 2022. "Endothelium-Dependent Relaxing Factors Market Analysis."
More… ↓
